GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envista Holdings Corp (NYSE:NVST) » Definitions » Peter Lynch Fair Value
中文

Envista Holdings (Envista Holdings) Peter Lynch Fair Value

: N/A (As of Today)
View and export this data going back to 2019. Start your Free Trial

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Envista Holdings's Peter Lynch Fair Value or its related term are showing as below:



NVST's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.545
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Envista Holdings Peter Lynch Fair Value Historical Data

The historical data trend for Envista Holdings's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envista Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - -

Envista Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Envista Holdings's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Envista Holdings Price-to-Peter-Lynch-Fair-Value Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Envista Holdings's Price-to-Peter-Lynch-Fair-Value falls into.



Envista Holdings Peter Lynch Fair Value Calculation

Envista Holdings's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *0.95
=N/A

Envista Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.95.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Envista Holdings  (NYSE:NVST) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Envista Holdings's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=20.22/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Envista Holdings Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Envista Holdings's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Envista Holdings (Envista Holdings) Business Description

Traded in Other Exchanges
Address
200 S. Kraemer Boulevard, Building E, Brea, CA, USA, 92821
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments comprising Specialty Products and Technologies and Equipment and Consumables. The Company's Specialty Products & Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Company's Equipment & Consumables segment manufactures dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.
Executives
Eric Conley officer: SVP, Orthodontics 200 S. KRAEMER BLVD, BLDG E, BREA CA 92821
Mark E Nance officer: Senior Vice President, GC, Sec 1333 S SPECTRUM BLVD #100, CHANDLER AZ 85286
Stephen Keller officer: Principal Financial Officer 200 S. KRAEMER BLVD., BUILDING E, BREA CA 92821
Amir Aghdaei director, officer: PRESIDENT AND CEO C/O CREDENCE SYSTEMS CORPORATION, 1421 CALIFORNIA CIRCLE, MILPITAS CA 95035
Faez C Kaabi officer: Chief Accounting Officer 200 S. KRAEMER BLVD., BUILDING E, BREA CA 92821
Howard H Yu officer: SENIOR VICE PRESIDENT, CFO 250 S. KRAEMER BLVD., BREA CA 92821
Mischa Reis officer: SENIOR VICE PRESIDENT C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD, BLDG. E, BREA CA 92821
Curt W Bludworth officer: SENIOR VICE PRESIDENT, CHRO 250 S. KRAEMER BLVD., BREA CA 92821
Barbara B. Hulit director C/O FORTIVE CORPORATION, 6920 SEAWAY BLVD, EVERETT WA 98203
Jeffrey Kappler officer: SENIOR VICE PRESIDENT C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD, BLDG. E, BREA CA 92821
Teresa Gayle Sheppard director C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD., BLDG. E, BREA CA 92821
Vivek Jain director ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Jean-claude Kyrillos officer: Senior Vice President C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD., BLDG. E, BREA CA 92821
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
William K Daniel director 2135 WEST MAPLE ROAD, TROY MI 48084